首页> 美国卫生研究院文献>Journal of Breast Cancer >Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Initial Axillary Lymph Node Metastasis after Primary Systemic Therapy
【2h】

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Initial Axillary Lymph Node Metastasis after Primary Systemic Therapy

机译:乳腺癌患者初次全身治疗后初次腋窝淋巴结转移的前哨淋巴结活检的可行性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposePrimary systemic therapy (PST) downstages up to 40% of initial documented axillary lymph node (ALN) metastases in breast cancer. The current surgical treatment after PST consists of breast tumor resection and axillary lymph node dissection (ALND). This strategy, however, does not eliminate unnecessary ALND in patients with complete remission of axillary metastases. The aim of this study was to examine the accuracy of sentinel lymph node biopsy (SLNB) after PST among patients with documented ALN metastasis at presentation and to identify the rate of pathologic complete-remission (CR) with ALN after PST.
机译:目的初步全身治疗(PST)可以降低乳腺癌中最初记录的腋窝淋巴结(ALN)转移的40%。 PST后目前的手术治疗包括乳腺肿瘤切除和腋窝淋巴结清扫(ALND)。然而,这种策略不能消除腋窝转移完全缓解的患者不必要的ALND。这项研究的目的是检查在PST后行ALN转移的患者中PST后前哨淋巴结活检(SLNB)的准确性,并确定PST后ALN的病理完全缓解(CR)率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号